» Pancreatic cancer: Oncodesign Precision Medicine and Servier will collaborate to discover new therapeutic targets MyPharma Editions

Pancreatic cancer Oncodesign Precision Medicine and Servier will collaborate

Posted on Friday, September 23, 2022 Servier, an international pharmaceutical group, and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign specializing in precision medicine, announce a collaborative research agreement, called “STarT Pancreas”, for the identification and validation of new therapeutic targets aimed at the development of new treatments for pancreatic ductal adenocarcinoma (PDAC). For a … Read more

Oncodesign Precision Medicine (OPM) and Servier announce the signing of a strategic collaboration for the discovery of new therapeutic targets in the treatment of pancreatic cancer – La Bourse et la Vie TV

Oncodesign Precision Medicine OPM and Servier announce the signing of

Identification and validation of new therapeutic targets against pancreatic cancer Construction of a common Artificial Intelligence (AI) analytical platform Generation and pooling of clinical and biological data, AI tools and skills in experimental pharmacology Servier can initiate a partnership with OPM in Drug Discovery based on certain targets discovered thanks to this technological approach SURESNES, … Read more

Oncodesign annonce ses résultats du 1er semestre 2022 : croissance de 28% du chiffre d’affaires de Service – La Bourse et la Vie TV L’information éco à valeur ajoutée

Oncodesign annonce ses resultats du 1er semestre 2022 croissance

CA Groupe de 16,8 M€ principalement porté par la forte croissance organique du Service avec un CA externe à 16,2 M€ (+28%) et avec un carnet de commandes de 17,8 M€ (+14%) Stabilité des revenus et produits d’exploitation à 19,3 M€ (+5%) Résultat d’exploitation en baisse à -1,8 M€, en raison de la hausse généralisée … Read more